Wednesday, September 8, 2021
09-08-2021-0937 - Primary myelofibrosis (PMF) is a rare bone marrow blood cancer.[1] ' This is most often associated with a somatic mutation in the JAK2, CALR, or MPL gene markers. In PMF, the healthy marrow is replaced by scar tissue (fibrosis), '
Primary myelofibrosis (PMF) is a rare bone marrow blood cancer.[1] It is classified by the World Health Organization (WHO) as a type of myeloproliferative neoplasm, a group of cancers in which there is growth of abnormal cells in the bone marrow. This is most often associated with a somatic mutation in the JAK2, CALR, or MPL gene markers. In PMF, the healthy marrow is replaced by scar tissue (fibrosis), resulting in a lack of production of normal blood cells. Symptoms include anemia, increased infection and an enlarged spleen (splenomegaly).
In 2016, prefibrotic primary myelofibrosis was formally classified as a distinct condition that progresses to overt PMF in many patients, the primary diagnostic difference being the grade of fibrosis.[2]
Primary myelofibrosis | |
---|---|
Other names | PMF, Overt PMF, Myelofibrosis |
Specialty | Oncology and Hematology |
https://en.wikipedia.org/wiki/Primary_myelofibrosis
Arrhythmogenic cardiomyopathy | |
---|---|
Other names | arrhythmogenic right ventricular cardiomyopathy (ARVC), arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), right ventricular dysplasia |
Typical micro-histologic features of ARVC/D. Ongoing myocyte death (upper) with early fibrosis and adipocyte infiltration (lower). | |
Specialty | Cardiology |
No comments:
Post a Comment